Kiyomi Ito

Prof. Kiyomi Ito


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
TNTomohisa Nakada
Tomohisa Nakada
TKToshiyuki Kudo
Toshiyuki Kudo
TKToshiyuki Kume
Toshiyuki Kume
HKHiroyuki Kusuhara
Hiroyuki Kusuhara
KIKiyomi Ito
Kiyomi Ito

1 December 2021 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Open access
KMKazuya Maeda
Kazuya Maeda
AHAkihiro Hisaka
Akihiro Hisaka
KIKiyomi Ito
Kiyomi Ito
YOYoshiyuki Ohno
Yoshiyuki Ohno
AIAkihiro Ishiguro
Akihiro Ishiguro
NNNaomi Nagai
Naomi Nagai
During new drug development, clinical drug interaction studies are carried out in accordance with the mechanism of potential drug interactions evaluated by in vitro studies. The obtained information should be provided efficiently to medical experts through package inserts and various information materials after the drug's launch. A recently updated Japanese guideline presents general procedures that are considered scientifically valid at the present moment. In this review, we aim to highlight the viewpoints of the Japanese guideline and enumerate drugs that were involved or are anticipated to be involved in evident pharmacokinetic drug interactions and classify them by their clearance pathway and potential intensity based on systematic reviews of the literature. The classification would be informative for designing clinical studies during the development stage, and the appropriate management of drug interactions in clinical practice.

1 February 2018 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
TNTomohisa Nakada
Tomohisa Nakada
TKToshiyuki Kudo
Toshiyuki Kudo
TKToshiyuki Kume
Toshiyuki Kume
HKHiroyuki Kusuhara
Hiroyuki Kusuhara
KIKiyomi Ito
Kiyomi Ito

19 March 2023 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
TNTomohisa Nakada
Tomohisa Nakada
TKToshiyuki Kudo
Toshiyuki Kudo
KIKiyomi Ito
Kiyomi Ito
Creatinine is a common biomarker of renal function and is secreted in the renal tubular cells via drug transporters such as organic cation transporter 2 and multidrug and toxin extrusion (MATE) 1/2-K. To differentiate between drug-induced acute kidney injury (AKI) and drug interactions through the renal transporter, it has been examined whether these transporter inhibitions quantitatively explained increases in serum creatinine (SCr) at their clinically relevant concentrations using drugs without any changes in renal function. For such renal transporter inhibitors and recently approved tyrosine kinase inhibitors (TKIs), this mini-review describes clinical increases in SCr and inhibitory potentials against the renal transporters. Most cases of SCr elevations can be explained by considering the renal transporter inhibitions based on unbound maximum plasma concentrations, except for drugs associated with obvious changes in renal function. SCr increases for cobicistat, dolutegravir, and dronedarone, and some TKIs were significantly underestimated, and these underestimations were suggested to be associated with low plasma unbound fractions. Sensitivity analysis of SCr elevations regarding inhibitory potentials of MATE1/2-K demonstrated that typical inhibitors such as cimetidine, DX-619, pyrimethamine, and trimethoprim could give false interpretations of AKI according to the criteria based on relative or absolute levels of SCr elevations. Recent progress and current challenges of physiologically-based pharmacokinetics modeling for creatinine disposition were also summarized. Although it should be noted for the potential impact of in vitro assay designs on clinical translatability of transporter inhibitions data, mechanistic approaches could support decision-making in clinical development to differentiate between AKI and creatinine-drug interactions. Significance Statement Serum creatinine (SCr) is widely used as an indicator of kidney function, but it increases due to inhibitions of renal transporters such as multidrug and toxin extrusion protein ½-K despite no functional changes in the kidney. Such SCr elevations were quantitatively explained by renal transporter inhibitions except for some drugs with high protein binding. The present analysis demonstrated that clinically relevant inhibitors of the renal transporters could cause SCr elevations above levels corresponding to acute kidney injury criteria.

1 November 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
KOKazuhisa Ozeki
Kazuhisa Ozeki
MKMotohiro Kato
Motohiro Kato
YSYuuji Sakurai
Yuuji Sakurai
MIMasaki Ishigai
Masaki Ishigai
TKToshiyuki Kudo
Toshiyuki Kudo
KIKiyomi Ito
Kiyomi Ito